efbemalenograstim alfa (Rx)

Brand and Other Names:Ryzneuta, efbemalenograstim alfa-vuxw

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable SC solution

  • 20mg/mL single-dose prefilled syringe

Febrile Neutropenia

Indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies who are receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia

20 mg SC once per chemotherapy cycle given at least 24 hr after cytotoxic chemotherapy

Do not administer within 14 days before and <24 hr after administration of chemotherapy

Dosage Modifications

Renal or hepatic impairment

  • Pharmacokinetics are unknown

Dosing Considerations

Limitation of use: Not indicated for mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation

Safety and efficacy not established

Next:

Adverse Effects

>10%

Nausea (51%)

Anemia (15%)

Thrombocytopenia (12%)

Previous
Next:

Warnings

Contraindications

History of serious allergic reactions to granulocyte stimulating factor (eg, efbemalenograstim alfa, pegfilgrastim, filgrastim)

Cautions

Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture

Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress; discontinue if ARDS confirmed

Serious allergic reactions, including anaphylaxis: Permanently discontinue

Sickle cell crises in patients with sickle cell disorders: Discontinue if sickle cell crisis occurs

Glomerulonephritis: Evaluate and consider dose reduction or interruption if causality is likely

Leukocytosis: WBC counts of 100 × ≥109 /L observed in patients receiving recombinant human granulocyte colony-stimiulating factor (rhG-CSF) products; monitor complete blood count (CBC) count during therapy; discontinue if WBC count exceeds 100 × 109/L

Thrombocytopenia: Monitor platelet counts

Capillary leak syndrome: Monitor symptoms; consider intensive care

Potential for tumor growth

  • The G-CSF receptor, through which efbemalenograstim alfa acts, has been found on tumor cell lines
  • The possibility exists that efbemalenograstim alfa could act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which it is not approved

Myelodysplasia and myeloid malignancy

  • Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with breast and lung cancer
  • Monitor patients with breast and lung cancer using efbemalenograstim alfa in conjunction with chemotherapy and/or radiotherapy for signs and symptoms of MDS/AML

Aortitis

  • Aortitis reported in patients receiving rhG-CSF products, occurring as early as the first week after starting therapy
  • Manifestations may include generalized signs and symptoms (eg, fever, abdominal pain, malaise, back pain, and increased inflammatory markers [eg, C-reactive protein, WBC count])
  • Consider aortitis in patients who develop these signs and symptoms without other known etiology
  • Discontinue if aortitis suspected

Nuclear imaging

  • Increased hematopoietic activity of bone marrow in response to growth factor therapy associated with transient positive bone imaging changes
  • Consider this when interpreting bone imaging results
Previous
Next:

Pregnancy & Lactation

Pregnancy

Available data regarding use in pregnant females are insufficient to establish drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes

Published studies data on with exposure to other human G-CSF products have not established an association of G-CSF product use during pregnancy with major birth defects, miscarriage, or adverse maternal or fetal outcomes

Animal studies

  • No evidence of reproductive/developmental toxicity occurred in offspring of pregnant rats and rabbits that received cumulative doses of efbemalenograstim alfa ~2.6 and 0.7 times, respectively, the recommended human dose (based on body surface area)

Lactation

Data are unavailable on presence of efbemalenograstim alfa or its metabolite in either human or animal milk, effects on breastfed children, or effects on milk production

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation

Absorption

Peak plasma time

  • Cycle 1: 36 hr
  • Cycle 3: 24-30 hr

Peak plasma concentration

  • Cycle 1: 1,085 ng/mL
  • Cycle 3: 525 ng/mL

AUC

  • Cycle 1: 54,858 hr⋅ng/mL
  • Cycle 3: 26,217 hr⋅ng/mL

Distribution

Vd

  • Cycle 1: 18.8 L
  • Cycle 3: 40.7 L

Metabolism

Expected to be metabolized into small peptides by catabolic pathways

Elimination

Half-life

  • Cycle 1: 35.6 hr
  • Cycle 3: 36.9 hr

Clearance

  • Cycle 1: 0.36 L/hr
  • Cycle 3: 0.76 L/hr
  • Neutrophil receptor binding is an important component of efbemalenograstim alfa clearance and is directly related to number of neutrophils
Previous
Next:

Administration

SC Preparation

Remove from refrigerator (keep prefilled syringe inside carton) at least 30 minutes before administering, to allow product to reach room temperature

Discard any product left at room temperature >48 hr

Inspect visually for particulate matter and discoloration before administration

Solution should appear clear and colorless; discard if discoloration or particulates observed

Do not administer to patients with latex allergy; product contains natural rubber latex, which may cause allergic reactions; needle cap on prefilled syringe contains natural rubber

Prefilled syringe does not bear graduation marks and is intended only to deliver the entire syringe contents (20 mg/mL) for direct administration

SC Administration

Administer SC by a healthcare professional

Administer injection by pinching skin and holding

Inject into abdomen, back or side of upper arms, or thighs

Rotate injection sites

Do not inject into scar tissue or areas that are reddened, inflamed, or swollen

If injecting into abdomen, avoid a 2-inch diameter circle around navel

Once entire dose has been injected, needle safety device will be triggered, pulling needle automatically from skin, and into barrel; entire needle will be covered by needle guard

Storage

Refrigerate at 2-8ºC (36-46ºF) in carton to protect from light

Do not shake

Discard syringes stored at room temperature >48 hr

Do not freeze; discard syringe if frozen

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.